前列腺癌治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Prostate Cancer Therapeutics Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月10日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在全球前列腺癌盛行率上升的推動下，2024-2032年前列腺癌治療市場規模將以8.8%的複合年成長率成長。根據《刺胳針》報道，攝護腺癌是 112 個國家男性中最常見的癌症，佔所有癌症病例的 15%。隨著對疾病早期檢測和診斷的更廣泛認知，需要能夠解決從局部癌症到轉移性癌症的各個階段和形式的創新療法。研發投資的增加，導致新藥和治療方式的推出，將促進市場成長。

人們越來越關注微創治療方案。與傳統手術方法相比，腹腔鏡手術、機器人輔助手術以及高強度聚焦超音波 (HIFU) 和冷凍療法等局部療法可提供更短的恢復時間、更少的併發症以及更好地保存正常組織。醫療技術的進步、患者意識的提高以及對維持生活品質的治療的日益偏好正在塑造市場前景。

前列腺癌治療行業根據治療、藥物類別、給藥途徑、配銷通路和地區進行分類。

到 2032 年，化療領域將快速成長。包括新藥物和治療方案在內的下一代化療藥物的開發為先前治療選擇有限的轉移性前列腺癌患者帶來了新的希望。這些療法根據患者的個別情況量身定做，從而製定更個人化和有效的治療計劃。

PARP 抑制劑部分將在 2032 年獲得關注，因為它透過針對驅動癌症進展的特定途徑徹底改變了前列腺癌的治療。這些藥物在癌症對傳統荷爾蒙療法產生抗藥性的情況下特別有效。例如，恩雜魯胺和醋酸阿比特龍等 ARI 已成為治療去勢抵抗性前列腺癌 (CRPC) 的主要藥物，可提供顯著的生存益處。同樣，奧拉帕尼等 PARP 抑制劑的推出為治療具有特定基因突變的患者開闢了新途徑。

在發病率上升、意識增強和先進治療方案採用的推動下，到 2032 年，歐洲前列腺癌治療產業將出現可觀的成長。該地區還受益於強大的醫療基礎設施和有利的報銷政策，有助於獲得創新療法。此外，歐洲領先的製藥公司和研究機構的存在正在加速尖端治療方法的開發和商業化，增加行業價值。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Astellas Pharma Inc.
AstraZeneca Plc
Bayer AG
Dendreon Pharmaceuticals LLC.
Exelixis, Inc
Ferring B.V.
GlaxoSmithKline Plc
Ipsen Pharma
Johnson and Johnson
Novartis AG
Pfizer Inc.
Sanofi S.A
Sumitomo Pharma America, Inc.
Takeda Pharmaceutical Company Limited
Tolmar Inc.

簡介目錄

Product Code: 10189

Prostate Cancer Therapeutics Market size will grow at an 8.8% CAGR during 2024-2032, driven by the rising prevalence of prostate cancer globally. According to The Lancet, prostate cancer is the most prevalent cancer among men in 112 countries, accounting for 15% of all cancer cases. With wider cognizance of early detection and diagnosis of the disease, there is a need for innovative therapies that can address various stages and forms of the disease, from localized to metastatic cancer. The heightened investment in R and D, leading to the introduction of new drugs and treatment modalities, will bolster the market growth.

There is an increasing focus on minimally invasive treatment options. Therapies, such as laparoscopic surgery, robotic-assisted surgery, and focal therapies like high-intensity focused ultrasound (HIFU) and cryotherapy, offer shorter recovery times, fewer complications, and better preservation of normal tissue compared to traditional surgical methods. The advancements in medical technology, greater patient awareness, and a growing preference for treatments that maintain quality of life are shaping the market outlook.

The prostate cancer therapeutics industry is classified based on therapy, drug class, route of administration, distribution channel, and region.

The chemotherapy segment will grow rapidly through 2032. New and improved chemotherapeutic agents, along with combination therapies, are enhancing patient outcomes by targeting cancer cells more effectively while minimizing side effects. The development of next-generation chemotherapies, including novel agents and regimens, is offering new hope to patients with metastatic prostate cancer, who previously had limited treatment options. These therapies are being tailored to individual patient profiles, leading to more personalized and effective treatment plans.

The PARP inhibitor segment will gain traction through 2032, as it has revolutionized prostate cancer treatment by targeting specific pathways that drive cancer progression. These drugs are particularly effective in cases where the cancer has become resistant to traditional hormone therapies. For instance, ARIs like enzalutamide and abiraterone acetate have become mainstays in treating castration-resistant prostate cancer (CRPC), providing significant survival benefits. Similarly, the introduction of PARP inhibitors such as Olaparib has opened new avenues for treating patients with specific genetic mutations.

Europe prostate cancer therapeutics industry will witness decent growth through 2032, driven by increasing incidence rates, growing awareness, and the adoption of advanced treatment options. The region is also benefiting from robust healthcare infrastructure and favorable reimbursement policies, which are facilitating access to innovative therapies. Moreover, the presence of leading pharmaceutical companies and research institutions in Europe is accelerating the development and commercialization of cutting-edge treatments, adding to industry value.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of prostate cancer
  - 3.2.1.2 Technological advancements
  - 3.2.1.3 Rising awareness and screening programs
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
3.9 Future market trends
3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Hormonal therapy
5.3 Chemotherapy
5.4 Immunotherapy
5.5 Targeted therapy
5.6 Other therapies

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Androgen receptor inhibitors
6.3 GnRH receptor antagonist
6.4 PARP inhibitor
6.5 Immune checkpoint inhibitors
6.6 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Brick and mortar
8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa